A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with ...

Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase ...

Age at menopause may interact with factors related to the health of synapses, or nerve cell connections, to influence the risk of Alzheimer’s disease in women, a study found. Associations between ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Muna Therapeutics and GSK said they will collaborate to identify and validate new therapeutic targets for Alzheimer’s disease, a step that could pave the way for new treatments for the condition. The ...

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. “Cassava Sciences is a ...

Anavex Life Sciences’ investigational oral therapy Anavex 2-73 (blarcamesine) significantly slows cognitive and functional decline in people with early Alzheimer’s disease, according to a new data ...

Few caregivers have time to take naps, but I recently read study results in a June Sleep Health article that suggest short naps can benefit cognitive health. That could mean something as simple as a ...

On-demand treatment with BXCL501, an orally dissolving film formulation of dexmedetomidine, significantly eased episodes of agitation among Alzheimer’s disease patients in a Phase 3 clinical trial, ...

The U.S. Food and Drug Administration (FDA) has approved Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzheimer’s disease. With this approval, Rexulti has now become the ...